Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Translational Development Acquisition (TDAC) Accumulated Expenses (2023 - 2025)

Translational Development Acquisition's Accumulated Expenses history spans 3 years, with the latest figure at $75000.0 for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 60.96% to $75000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $75000.0, a 60.96% decrease, with the full-year FY2025 number at $75000.0, down 60.96% from a year prior.
  • Accumulated Expenses came in at $75000.0 for Q4 2025, roughly flat from $75000.0 in the prior quarter.
  • The five-year high for Accumulated Expenses was $192114.0 in Q4 2024, with the low at $75000.0 in Q1 2025.
  • Historically, Accumulated Expenses has averaged $108840.2 across 3 years, with a median of $75000.0 in 2025.
  • Biggest five-year swings in Accumulated Expenses: rose 19.38% in 2024 and later tumbled 60.96% in 2025.
  • Year by year, Accumulated Expenses stood at $160927.0 in 2023, then increased by 19.38% to $192114.0 in 2024, then plummeted by 60.96% to $75000.0 in 2025.
  • Business Quant data shows Accumulated Expenses for TDAC at $75000.0 in Q4 2025, $75000.0 in Q3 2025, and $75000.0 in Q2 2025.